Advancion Corporation announced the expansion of its U.S.-based manufacturing capabilities with the commercial launch of MOPS buffer produced at its Sterlington, Louisiana facility.
MOPS (3-(N-morpholino)propanesulfonic acid) is a zwitterionic biological buffer commonly used in cell culture and bioprocessing applications to maintain a stable, near-neutral pH. Its low reactivity and minimal interference with biological reactions make it ideal for applications such as protein purification, electrophoresis, cell lysis, and nucleic acid research. MOPS is also widely utilized in diagnostic assays and downstream bioprocessing steps where pH stability is critical to product quality and performance.
"The launch of commercial-scale MOPS production is a key step in strengthening Advancion's leadership in life science buffers," said Liam Doherty, Executive Vice President, Global Life Sciences. "Producing MOPS in-house at our Sterlington facility secures a dependable global supply while maintaining the highest standards of quality, purity, and compliance. This expansion underscores our commitment to transparent, reliable buffer manufacturing and to investing in capacity to fuel growth and innovation across the global biopharmaceutical industry."
MOPS buffer products are produced by Advancion under the Company's single Global Quality Management System, which includes ISO 9001:2015 certified in-process monitoring and facility control systems. Comprehensive quality testing is conducted using validated analytical methods, and may include elemental impurities by ICP-MS, endotoxin, bioburden, DNase, RNase, and protease.